triamcinolone acetonide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
steroids not used as glucocorticosteroids 2726 76-25-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nasacort
  • triamcinolone acetonide
  • aristicort
  • allernaze
An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.
  • Molecular weight: 434.50
  • Formula: C24H31FO6
  • CLOGP: 2.21
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 93.06
  • ALOGS: -4.01
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.11 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.26 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 23 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.20 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 4, 1960 FDA APOTHECON

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 327.11 11.76 159 27540 14229 50563196
Injection site atrophy 267.47 11.76 61 27638 453 50576972
Adrenal insufficiency 243.88 11.76 130 27569 14113 50563312
Soft tissue disorder 171.28 11.76 70 27629 4144 50573281
Skin atrophy 137.46 11.76 60 27639 4185 50573240
Joint destruction 132.19 11.76 57 27642 3859 50573566
Non-infectious endophthalmitis 124.68 11.76 26 27673 119 50577306
Endophthalmitis 117.01 11.76 48 27651 2868 50574557
Wheelchair user 116.13 11.76 56 27643 4916 50572509
Pneumonia viral 107.54 11.76 59 27640 6775 50570650
Arthritis 103.72 11.76 177 27522 86544 50490881
Body height below normal 102.45 11.76 39 27660 1910 50575515
Polyarthritis 102.00 11.76 60 27639 7867 50569558
Obesity 100.30 11.76 79 27620 16696 50560729
Human antichimeric antibody positive 97.43 11.76 35 27664 1454 50575971
Liver function test abnormal 85.23 11.76 113 27586 44226 50533199
Intraocular pressure increased 79.63 11.76 45 27654 5471 50571954
Toxicity to various agents 79.57 11.76 11 27688 212488 50364937
Fibromyalgia 76.44 11.76 108 27591 44870 50532555
Hypothalamic pituitary adrenal axis suppression 73.41 11.76 17 27682 136 50577289
Dermatitis atopic 70.71 11.76 36 27663 3550 50573875
Eye infection toxoplasmal 67.95 11.76 18 27681 262 50577163
Psoriasis 66.15 11.76 128 27571 68872 50508553
Gastroenteritis viral 65.19 11.76 65 27634 18721 50558704
Antibody test positive 60.00 11.76 28 27671 2283 50575142
Immunodeficiency 58.40 11.76 55 27644 14773 50562652
Synovitis 57.06 11.76 173 27526 123692 50453733
Cushing's syndrome 57.00 11.76 19 27680 629 50576796
Hypocalcaemia 55.66 11.76 71 27628 26745 50550680
Rhegmatogenous retinal detachment 54.27 11.76 12 27687 76 50577349
Blood cholesterol increased 53.61 11.76 103 27596 55112 50522313
Visual acuity reduced 52.73 11.76 60 27639 20079 50557346
Bone density decreased 49.30 11.76 44 27655 11031 50566394
Bursitis infective 48.45 11.76 20 27679 1214 50576211
Necrotising scleritis 48.22 11.76 12 27687 134 50577291
Retinal artery occlusion 48.08 11.76 21 27678 1466 50575959
Adrenal suppression 47.82 11.76 18 27681 854 50576571
Lipoatrophy 47.82 11.76 14 27685 299 50577126
Retinal pigment epithelial tear 46.55 11.76 13 27686 233 50577192
Ankle arthroplasty 46.47 11.76 19 27680 1125 50576300
Ocular hypertension 45.65 11.76 17 27682 783 50576642
Postmenopausal haemorrhage 45.33 11.76 22 27677 1958 50575467
Acute kidney injury 44.21 11.76 36 27663 228022 50349403
Injection site discolouration 44.19 11.76 34 27665 6940 50570485
Therapy non-responder 43.32 11.76 90 27609 50932 50526493
Urticarial vasculitis 43.18 11.76 15 27684 564 50576861
Secondary adrenocortical insufficiency 43.10 11.76 18 27681 1125 50576300
Intentional product use issue 42.76 11.76 115 27584 76803 50500622
Drug specific antibody 40.94 11.76 20 27679 1805 50575620
Herpes zoster 39.51 11.76 106 27593 70680 50506745
Bone density increased 38.20 11.76 13 27686 459 50576966
Tractional retinal detachment 37.14 11.76 8 27691 44 50577381
Death 36.72 11.76 77 27622 325302 50252123
Maculopathy 36.56 11.76 19 27680 1955 50575470
Human anti-human antibody test 36.12 11.76 12 27687 393 50577032
Septic shock 35.38 11.76 89 27610 57086 50520339
Therapeutic product effect incomplete 33.28 11.76 118 27581 91397 50486028
Skin discolouration 32.89 11.76 62 27637 32695 50544730
Atrophy 32.11 11.76 16 27683 1507 50575918
Eczema 30.68 11.76 49 27650 22653 50554772
Retinal detachment 30.32 11.76 24 27675 5105 50572320
Soft tissue swelling 29.03 11.76 13 27686 963 50576462
Drug ineffective 28.83 11.76 617 27082 818716 49758709
General physical health deterioration 28.19 11.76 22 27677 142412 50435013
Leukopenia 28.00 11.76 91 27608 67437 50509988
Skin hypopigmentation 27.42 11.76 11 27688 620 50576805
Keratitis fungal 27.08 11.76 7 27692 92 50577333
Hypopyon 26.80 11.76 11 27688 658 50576767
Short stature 26.69 11.76 9 27690 309 50577116
Dry skin 26.47 11.76 67 27632 43124 50534301
Chorioretinal folds 26.44 11.76 5 27694 12 50577413
Scleral thinning 26.16 11.76 5 27694 13 50577412
Retinal haemorrhage 26.14 11.76 21 27678 4560 50572865
Infective scleritis 26.04 11.76 4 27695 0 50577425
Eye inflammation 25.54 11.76 20 27679 4188 50573237
Product contamination 24.99 11.76 10 27689 560 50576865
Infection 24.88 11.76 171 27528 172783 50404642
Chorioretinopathy 24.56 11.76 11 27688 815 50576610
Blindness 24.34 11.76 38 27661 17231 50560194
Polypoidal choroidal vasculopathy 24.19 11.76 6 27693 66 50577359
Pruritus 24.06 11.76 249 27450 283319 50294106
Tenderness 23.63 11.76 39 27660 18526 50558899
Joint effusion 23.20 11.76 32 27667 12989 50564436
Cushingoid 23.06 11.76 23 27676 6622 50570803
Skin fissures 22.98 11.76 26 27673 8642 50568783
Hyperadrenocorticism 22.63 11.76 8 27691 317 50577108
Drug abuse 22.60 11.76 3 27696 59843 50517582
Thrombocytopenia 22.50 11.76 22 27677 127651 50449774
Nodule 22.02 11.76 36 27663 16967 50560458
Loss of personal independence in daily activities 21.85 11.76 86 27613 69964 50507461
Conjunctival ulcer 21.70 11.76 5 27694 39 50577386
Orbital infection 21.59 11.76 5 27694 40 50577385
Overdose 21.57 11.76 14 27685 99713 50477712
Staphylococcal infection 21.56 11.76 55 27644 35561 50541864
Oral pain 21.05 11.76 44 27655 24989 50552436
Cytomegalovirus chorioretinitis 20.96 11.76 12 27687 1495 50575930
Spinal cord infarction 20.71 11.76 7 27692 242 50577183
Vitreous opacities 20.57 11.76 7 27692 247 50577178
Arthritis bacterial 20.50 11.76 20 27679 5609 50571816
Exposure via breast milk 20.23 11.76 12 27687 1596 50575829
Retinal scar 19.95 11.76 6 27693 141 50577284
Intentional overdose 19.61 11.76 5 27694 62499 50514926
Acute febrile neutrophilic dermatosis 19.23 11.76 14 27685 2628 50574797
Injection site fibrosis 19.06 11.76 4 27695 19 50577406
Pseudoendophthalmitis 18.89 11.76 4 27695 20 50577405
Purpura senile 18.84 11.76 8 27691 521 50576904
Systemic lupus erythematosus 18.74 11.76 30 27669 140592 50436833
Renal impairment 18.70 11.76 9 27690 75652 50501773
Quality of life decreased 18.66 11.76 20 27679 6263 50571162
Epicondylitis 18.34 11.76 12 27687 1897 50575528
Detachment of retinal pigment epithelium 18.25 11.76 7 27692 350 50577075
Dermatitis contact 18.10 11.76 23 27676 8623 50568802
Ophthalmic herpes simplex 17.97 11.76 7 27692 365 50577060
Red blood cell sedimentation rate abnormal 17.74 11.76 32 27667 16311 50561114
Vitreous disorder 17.73 11.76 5 27694 93 50577332
Eye infection fungal 17.53 11.76 5 27694 97 50577328
Neutropenia 17.52 11.76 34 27665 147931 50429494
Impaired quality of life 17.49 11.76 19 27680 6037 50571388
Conjunctival haemorrhage 17.47 11.76 14 27685 3030 50574395
Pyloric abscess 17.46 11.76 3 27696 3 50577422
Infective uveitis 17.46 11.76 3 27696 3 50577422
Red blood cell sedimentation rate increased 17.37 11.76 45 27654 29371 50548054
Peripheral vascular disorder 17.29 11.76 18 27681 5449 50571976
Chronic sinusitis 17.27 11.76 19 27680 6126 50571299
Foot operation 17.18 11.76 18 27681 5492 50571933
Bradycardia 16.96 11.76 7 27692 64419 50513006
Wound 16.67 11.76 20 27679 105774 50471651
Resorption bone increased 16.66 11.76 9 27690 1002 50576423
Conjunctivitis allergic 16.50 11.76 8 27691 710 50576715
Endometrial thickening 16.37 11.76 6 27693 264 50577161
Injection site abscess 16.34 11.76 9 27690 1040 50576385
Periorbital abscess 16.24 11.76 3 27696 6 50577419
Rapidly progressive osteoarthritis 15.93 11.76 3 27696 7 50577418
Product use in unapproved indication 15.76 11.76 113 27586 115706 50461719
Hypokalaemia 15.74 11.76 92 27607 87900 50489525
Necrotising retinitis 15.70 11.76 6 27693 297 50577128
Muscle atrophy 15.62 11.76 18 27681 6103 50571322
Tarsal tunnel syndrome 15.46 11.76 7 27692 532 50576893
Dermatophytosis 15.31 11.76 5 27694 155 50577270
Limb discomfort 15.15 11.76 38 27661 24319 50553106
Aspirin-exacerbated respiratory disease 15.01 11.76 8 27691 866 50576559
Injection site necrosis 14.99 11.76 9 27690 1224 50576201
Retinal artery embolism 14.99 11.76 4 27695 60 50577365
Skin exfoliation 14.57 11.76 46 27653 33566 50543859
Drug specific antibody present 14.24 11.76 13 27686 3355 50574070
Ear discomfort 14.21 11.76 18 27681 6726 50570699
Iridoschisis 14.17 11.76 3 27696 15 50577410
Cardiac arrest 14.07 11.76 15 27684 83636 50493789
Corneal oedema 14.02 11.76 9 27690 1378 50576047
Retinitis viral 14.00 11.76 3 27696 16 50577409
Cardio-respiratory arrest 13.95 11.76 6 27693 53886 50523539
Diabetic ulcer 13.93 11.76 5 27694 207 50577218
Choroidal infarction 13.86 11.76 4 27695 81 50577344
Retinal exudates 13.84 11.76 7 27692 681 50576744
Upper respiratory tract infection bacterial 13.73 11.76 4 27695 84 50577341
Cross sensitivity reaction 13.36 11.76 10 27689 1959 50575466
Autoimmune colitis 13.35 11.76 6 27693 448 50576977
Glossodynia 13.29 11.76 27 27672 115542 50461883
Mobility decreased 13.28 11.76 82 27617 79866 50497559
Vertigo positional 13.26 11.76 11 27688 2500 50574925
Retinal occlusive vasculitis 13.18 11.76 3 27696 22 50577403
Pemphigus 13.05 11.76 29 27670 120137 50457288
Peripheral swelling 13.05 11.76 171 27528 205765 50371660
Parakeratosis 12.81 11.76 5 27694 262 50577163
Maternal exposure during pregnancy 12.59 11.76 45 27654 159733 50417692
Spinal cord ischaemia 12.54 11.76 3 27696 28 50577397
Retinal vasculitis 12.54 11.76 7 27692 831 50576594
Glaucoma 12.53 11.76 27 27672 15659 50561766
Steroid withdrawal syndrome 12.50 11.76 6 27693 521 50576904
Injection site scar 12.45 11.76 7 27692 842 50576583
Allergic reaction to excipient 12.41 11.76 5 27694 285 50577140
Injection site calcification 12.36 11.76 3 27696 30 50577395
Seizure 12.35 11.76 29 27670 117845 50459580
Bronchiectasis 12.28 11.76 21 27678 10262 50567163
Respiratory tract infection 12.25 11.76 42 27657 31975 50545450
Prescribed underdose 12.22 11.76 27 27672 15922 50561503
Cataract subcapsular 12.10 11.76 6 27693 559 50576866
Pancytopenia 12.09 11.76 17 27682 84013 50493412
Foot deformity 11.97 11.76 30 27669 19180 50558245
Infusion related reaction 11.92 11.76 50 27649 169507 50407918
Tendon rupture 11.90 11.76 17 27682 7127 50570298
Retinal ischaemia 11.86 11.76 5 27694 320 50577105
Rotator cuff syndrome 11.77 11.76 22 27677 11522 50565903

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Endophthalmitis 236.39 13.44 72 10426 2776 29561253
Non-infectious endophthalmitis 180.39 13.44 33 10465 112 29563917
Visual acuity reduced 137.56 13.44 78 10420 14798 29549231
Ocular hypertension 122.78 13.44 32 10466 690 29563339
Hypothalamic pituitary adrenal axis suppression 87.62 13.44 18 10480 126 29563903
Infective scleritis 87.52 13.44 14 10484 14 29564015
Chorioretinopathy 85.10 13.44 28 10470 1388 29562641
Maculopathy 81.28 13.44 24 10474 829 29563200
Intraocular pressure increased 75.66 13.44 36 10462 4753 29559276
Eye infection toxoplasmal 70.61 13.44 16 10482 186 29563843
Dermatitis atopic 69.25 13.44 27 10471 2192 29561837
Dry skin 65.30 13.44 59 10439 23248 29540781
Adrenal suppression 64.23 13.44 18 10480 514 29563515
Intentional product use issue 60.54 13.44 75 10423 42423 29521606
Macular oedema 59.78 13.44 25 10473 2433 29561596
Injection site atrophy 58.90 13.44 11 10487 43 29563986
Hypopyon 57.38 13.44 15 10483 327 29563702
Eye inflammation 54.21 13.44 21 10477 1675 29562354
Retinal artery occlusion 51.54 13.44 20 10478 1603 29562426
Skin fissures 48.64 13.44 25 10473 3894 29560135
Symmetrical drug-related intertriginous and flexural exanthema 48.02 13.44 12 10486 217 29563812
Necrotising scleritis 47.64 13.44 9 10489 38 29563991
Glaucoma 46.92 13.44 28 10470 5829 29558200
Skin exfoliation 45.89 13.44 48 10450 22597 29541432
Retinal haemorrhage 42.63 13.44 24 10474 4480 29559549
Macular fibrosis 42.22 13.44 12 10486 361 29563668
Necrotising retinitis 41.42 13.44 14 10484 754 29563275
Pruritus 40.97 13.44 112 10386 116737 29447292
Product contamination 40.27 13.44 13 10485 606 29563423
Dermatitis contact 39.79 13.44 20 10478 2972 29561057
Toxicity to various agents 39.56 13.44 7 10491 173654 29390375
Retinal artery embolism 37.98 13.44 7 10491 25 29564004
Pseudoendophthalmitis 34.86 13.44 7 10491 43 29563986
Vitreous opacities 32.85 13.44 9 10489 236 29563793
Uveitis-glaucoma-hyphaema syndrome 32.37 13.44 5 10493 3 29564026
Skin hypopigmentation 32.08 13.44 9 10489 258 29563771
Cystoid macular oedema 31.98 13.44 11 10487 625 29563404
Retinal detachment 31.42 13.44 20 10478 4666 29559363
Injection site calcification 31.26 13.44 5 10493 5 29564024
Psoriasis 30.91 13.44 47 10451 32180 29531849
Diabetic retinal oedema 30.28 13.44 8 10490 182 29563847
Rhegmatogenous retinal detachment 30.00 13.44 6 10492 36 29563993
Retinal pigment epithelial tear 27.98 13.44 8 10490 246 29563783
Cross sensitivity reaction 27.91 13.44 12 10486 1250 29562779
Anaphylactic reaction 27.57 13.44 41 10457 27532 29536497
Product use issue 27.37 13.44 58 10440 51386 29512643
Vitritis 27.30 13.44 10 10488 683 29563346
Rash 27.12 13.44 136 10362 189683 29374346
Eye abscess 27.02 13.44 7 10491 147 29563882
Subretinal fluid 26.38 13.44 8 10490 303 29563726
Open globe injury 25.54 13.44 4 10494 3 29564026
Drug ineffective 25.29 13.44 217 10281 362953 29201076
Blindness 25.27 13.44 26 10472 11997 29552032
Choroidal infarction 25.19 13.44 6 10492 88 29563941
Cauda equina syndrome 24.46 13.44 8 10490 389 29563640
Expired product administered 23.98 13.44 14 10484 2797 29561232
Eczema 23.97 13.44 27 10471 13799 29550230
Arthritis infective 23.92 13.44 14 10484 2810 29561219
Anterior chamber inflammation 23.72 13.44 7 10491 241 29563788
Optic nerve compression 23.39 13.44 4 10494 8 29564021
Adrenal insufficiency 23.30 13.44 24 10474 11090 29552939
Distal intestinal obstruction syndrome 23.16 13.44 7 10491 262 29563767
Spinal cord infarction 22.93 13.44 7 10491 271 29563758
Uveitis 22.70 13.44 18 10480 5929 29558100
Eye pain 22.45 13.44 24 10474 11571 29552458
Central vision loss 21.55 13.44 4 10494 15 29564014
Pain 21.15 13.44 118 10380 171314 29392715
Pneumonia lipoid 20.88 13.44 5 10493 75 29563954
Vision blurred 19.88 13.44 44 10454 40132 29523897
Retinal degeneration 19.72 13.44 7 10491 437 29563592
Oesophageal perforation 19.44 13.44 8 10490 747 29563282
Visual field defect 19.11 13.44 14 10484 4102 29559927
Incorrect route of product administration 18.56 13.44 21 10477 10780 29553249
Eye pruritus 18.47 13.44 14 10484 4318 29559711
Cardiac arrest 18.31 13.44 4 10494 85587 29478442
Product use in unapproved indication 18.29 13.44 70 10428 86805 29477224
Arthritis bacterial 18.24 13.44 14 10484 4399 29559630
Cellulitis orbital 18.20 13.44 6 10492 299 29563730
Retinal oedema 18.10 13.44 7 10491 556 29563473
Cataract 17.83 13.44 30 10468 22348 29541681
Eye infection fungal 17.83 13.44 6 10492 319 29563710
Visual impairment 17.56 13.44 35 10463 29673 29534356
Chorioretinal folds 17.54 13.44 3 10495 6 29564023
Cytomegalovirus chorioretinitis 17.30 13.44 12 10486 3226 29560803
Anterior spinal artery syndrome 17.22 13.44 3 10495 7 29564022
Cataract subcapsular 17.11 13.44 6 10492 361 29563668
Anal ulcer 17.04 13.44 7 10491 651 29563378
Infective uveitis 16.94 13.44 3 10495 8 29564021
Eye swelling 16.90 13.44 18 10480 8639 29555390
Drug abuse 16.55 13.44 4 10494 79879 29484150
Amblyopia 16.35 13.44 4 10494 66 29563963
Lenticular opacities 16.32 13.44 5 10493 196 29563833
Intracranial hypotension 15.90 13.44 5 10493 214 29563815
Inadequate aseptic technique in use of product 15.63 13.44 3 10495 14 29564015
Cortisol decreased 15.46 13.44 7 10491 824 29563205
Hyperlipasaemia 15.46 13.44 6 10492 481 29563548
Mycobacterium kansasii infection 15.33 13.44 5 10493 241 29563788
Application site pruritus 15.30 13.44 8 10490 1289 29562740
Subretinal fibrosis 14.90 13.44 4 10494 97 29563932
Conjunctivitis 14.51 13.44 16 10482 7982 29556047
Scleral disorder 14.48 13.44 3 10495 22 29564007
Vitrectomy 14.21 13.44 4 10494 116 29563913
Cutaneous nocardiosis 13.60 13.44 4 10494 136 29563893

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Non-infectious endophthalmitis 278.17 11.32 56 30380 249 64468047
Endophthalmitis 277.70 11.32 102 30334 5263 64463033
Injection site atrophy 266.33 11.32 56 30380 321 64467975
Adrenal insufficiency 234.64 11.32 141 30295 22346 64445950
Visual acuity reduced 148.20 11.32 114 30322 27027 64441269
Ocular hypertension 145.97 11.32 44 30392 1217 64467079
Intraocular pressure increased 144.52 11.32 73 30363 8229 64460067
Joint destruction 137.47 11.32 55 30381 3581 64464715
Eye infection toxoplasmal 136.14 11.32 34 30402 453 64467843
Toxicity to various agents 117.98 11.32 16 30420 363497 64104799
Hypothalamic pituitary adrenal axis suppression 115.47 11.32 27 30409 267 64468029
Skin atrophy 112.03 11.32 52 30384 4868 64463428
Soft tissue disorder 111.66 11.32 46 30390 3230 64465066
Maculopathy 109.31 11.32 42 30394 2454 64465842
Infective scleritis 108.97 11.32 18 30418 15 64468281
Wheelchair user 108.32 11.32 50 30386 4622 64463674
Adrenal suppression 98.48 11.32 33 30403 1294 64467002
Human antichimeric antibody positive 96.38 11.32 33 30403 1383 64466913
Chorioretinopathy 96.33 11.32 37 30399 2160 64466136
Body height below normal 95.68 11.32 35 30401 1783 64466513
Retinal artery occlusion 93.00 11.32 39 30397 2864 64465432
Completed suicide 92.38 11.32 3 30433 224411 64243885
Intentional product use issue 92.02 11.32 163 30273 95201 64373095
Polyarthritis 91.29 11.32 57 30379 9658 64458638
Obesity 90.21 11.32 76 30360 20486 64447810
Necrotising scleritis 87.32 11.32 20 30416 179 64468117
Pneumonia viral 86.65 11.32 51 30385 7771 64460525
Dermatitis atopic 85.26 11.32 40 30396 3836 64464460
Rhegmatogenous retinal detachment 82.38 11.32 18 30418 127 64468169
Arthritis 81.81 11.32 144 30292 83670 64384626
Retinal pigment epithelial tear 76.54 11.32 21 30415 411 64467885
Psoriasis 76.29 11.32 128 30308 71575 64396721
Cushing's syndrome 68.00 11.32 23 30413 928 64467368
Gastroenteritis viral 66.82 11.32 63 30373 19666 64448630
Hypopyon 66.23 11.32 23 30413 1006 64467290
Retinal haemorrhage 63.51 11.32 41 30395 7357 64460939
Retinal detachment 63.10 11.32 42 30394 7934 64460362
Immunodeficiency 61.44 11.32 55 30381 16069 64452227
Product contamination 57.82 11.32 21 30415 1048 64467248
Synovitis 56.09 11.32 136 30300 98954 64369342
Fibromyalgia 55.35 11.32 76 30360 35655 64432641
Bone density decreased 54.74 11.32 42 30394 9910 64458386
Necrotising retinitis 54.22 11.32 20 30416 1043 64467253
Dry skin 53.96 11.32 91 30345 51070 64417226
Blindness 52.16 11.32 58 30378 21961 64446335
Eye inflammation 52.05 11.32 31 30405 4826 64463470
Acute kidney injury 51.44 11.32 83 30353 449157 64019139
Vitreous opacities 51.43 11.32 16 30420 493 64467803
Antibody test positive 50.36 11.32 24 30412 2383 64465913
Pseudoendophthalmitis 49.94 11.32 10 30426 43 64468253
Ankle arthroplasty 49.76 11.32 18 30418 888 64467408
Dermatitis contact 49.54 11.32 38 30398 8962 64459334
Skin fissures 49.17 11.32 40 30396 10266 64458030
Chorioretinal folds 47.98 11.32 9 30427 25 64468271
Therapy non-responder 45.66 11.32 98 30338 65801 64402495
Death 44.10 11.32 102 30334 482603 63985693
Glaucoma 43.87 11.32 46 30390 16302 64451994
Skin hypopigmentation 43.00 11.32 16 30420 855 64467441
Pruritus 42.90 11.32 273 30163 312127 64156169
Drug abuse 42.46 11.32 6 30430 132368 64335928
Bone density increased 42.42 11.32 14 30422 523 64467773
Injection site discolouration 42.23 11.32 31 30405 6844 64461452
Injection site calcification 41.95 11.32 8 30428 25 64468271
Liver function test abnormal 41.92 11.32 89 30347 59312 64408984
Cytomegalovirus chorioretinitis 41.62 11.32 27 30409 4885 64463411
Spinal cord infarction 41.51 11.32 14 30422 560 64467736
Blood cholesterol increased 41.25 11.32 80 30356 49986 64418310
Drug specific antibody 41.14 11.32 20 30416 2075 64466221
Retinal artery embolism 40.77 11.32 10 30426 123 64468173
Arthritis bacterial 38.61 11.32 31 30405 7808 64460488
Human anti-human antibody test 38.38 11.32 12 30424 376 64467920
Product use issue 38.00 11.32 157 30279 151558 64316738
Choroidal infarction 37.61 11.32 10 30426 173 64468123
Cross sensitivity reaction 37.41 11.32 22 30414 3345 64464951
Macular oedema 36.99 11.32 25 30411 4842 64463454
Secondary adrenocortical insufficiency 36.13 11.32 19 30417 2326 64465970
Hypocalcaemia 35.98 11.32 68 30368 41685 64426611
Diabetic retinal oedema 35.45 11.32 11 30425 336 64467960
Scleral thinning 34.61 11.32 7 30429 32 64468264
Overdose 34.57 11.32 16 30420 159550 64308746
Vitritis 34.27 11.32 16 30420 1517 64466779
Tractional retinal detachment 33.95 11.32 8 30428 82 64468214
Symmetrical drug-related intertriginous and flexural exanthema 32.84 11.32 12 30424 609 64467687
Cardiac arrest 32.53 11.32 16 30420 154048 64314248
Eye abscess 32.52 11.32 10 30426 296 64468000
Lipoatrophy 32.40 11.32 12 30424 633 64467663
Hyperadrenocorticism 32.21 11.32 10 30426 306 64467990
Infective uveitis 32.17 11.32 6 30430 16 64468280
Cataract subcapsular 32.06 11.32 13 30423 876 64467420
General physical health deterioration 31.50 11.32 30 30406 204395 64263901
Skin exfoliation 31.37 11.32 67 30369 44818 64423478
Macular fibrosis 31.21 11.32 12 30424 702 64467594
Exposure via breast milk 29.98 11.32 12 30424 782 64467514
Cataract 29.68 11.32 71 30365 51191 64417105
Joint effusion 29.38 11.32 34 30402 13439 64454857
Thrombocytopenia 28.84 11.32 38 30398 223763 64244533
Short stature 28.72 11.32 9 30427 284 64468012
Eye infection fungal 28.71 11.32 10 30426 441 64467855
Subretinal fluid 28.47 11.32 11 30425 652 64467644
Keratitis fungal 28.23 11.32 8 30428 177 64468119
Therapeutic product effect incomplete 28.22 11.32 110 30326 103372 64364924
Incorrect route of product administration 28.03 11.32 44 30392 23254 64445042
Coma 28.03 11.32 4 30432 87611 64380685
Eye pain 27.86 11.32 52 30384 31573 64436723
Bradycardia 26.96 11.32 11 30425 118208 64350088
Staphyloma 26.64 11.32 4 30432 0 64468296
Retinal degeneration 26.56 11.32 12 30424 1055 64467241
Polypoidal choroidal vasculopathy 26.55 11.32 8 30428 221 64468075
Cystoid macular oedema 26.28 11.32 14 30422 1760 64466536
Ophthalmic herpes simplex 26.19 11.32 10 30426 574 64467722
Soft tissue swelling 26.19 11.32 12 30424 1090 64467206
Neutropenia 25.78 11.32 46 30390 239578 64228718
Rhabdomyolysis 25.45 11.32 6 30430 91720 64376576
Corneal oedema 25.22 11.32 15 30421 2328 64465968
Eczema 25.10 11.32 48 30388 29672 64438624
Orbital infection 24.91 11.32 6 30430 68 64468228
Loss of personal independence in daily activities 24.84 11.32 83 30353 72371 64395925
Intentional overdose 24.73 11.32 6 30430 89938 64378358
Nodule 24.58 11.32 36 30400 17911 64450385
Open globe injury 24.16 11.32 6 30430 78 64468218
Anaphylactic reaction 23.85 11.32 79 30357 68585 64399711
Cushingoid 23.33 11.32 23 30413 7580 64460716
Anal ulcer 23.03 11.32 11 30425 1098 64467198
Macular degeneration 22.79 11.32 20 30416 5690 64462606
Cardio-respiratory arrest 22.69 11.32 9 30427 98384 64369912
Retinal vasculitis 22.67 11.32 11 30425 1136 64467160
Retinal scar 22.24 11.32 8 30428 388 64467908
Skin discolouration 21.68 11.32 50 30386 35205 64433091
Oral pain 21.52 11.32 43 30393 27450 64440846
Foot operation 21.40 11.32 17 30419 4218 64464078
Detachment of retinal pigment epithelium 21.35 11.32 9 30427 669 64467627
Uveitis 21.15 11.32 28 30408 12680 64455616
Periorbital abscess 21.10 11.32 4 30432 12 64468284
Tenderness 20.84 11.32 35 30401 19567 64448729
Oesophageal perforation 20.63 11.32 10 30426 1031 64467265
Drug ineffective 20.60 11.32 530 29906 839717 63628579
Electrocardiogram QT prolonged 20.51 11.32 6 30430 79442 64388854
Optic nerve compression 20.41 11.32 4 30432 15 64468281
Product use in unapproved indication 20.40 11.32 148 30288 176470 64291826
Postmenopausal haemorrhage 20.34 11.32 11 30425 1424 64466872
Conjunctival ulcer 20.20 11.32 5 30431 64 64468232
Cauda equina syndrome 20.08 11.32 10 30426 1093 64467203
Atrophy 19.99 11.32 12 30424 1895 64466401
Red blood cell sedimentation rate increased 19.98 11.32 45 30391 31190 64437106
Tendon rupture 19.92 11.32 25 30411 10742 64457554
Red blood cell sedimentation rate abnormal 19.90 11.32 31 30405 16275 64452021
Herpes zoster 19.85 11.32 82 30354 79105 64389191
Cutaneous nocardiosis 19.47 11.32 6 30430 179 64468117
Staphylococcal infection 19.13 11.32 60 30376 50618 64417678
Impaired quality of life 18.79 11.32 19 30417 6452 64461844
Vitrectomy 18.64 11.32 6 30430 207 64468089
Renal impairment 18.35 11.32 22 30414 134995 64333301
Pyloric abscess 17.90 11.32 3 30433 3 64468293
Epicondylitis 17.74 11.32 11 30425 1840 64466456
Vitreous disorder 17.69 11.32 6 30430 244 64468052
Allergic reaction to excipient 17.65 11.32 6 30430 246 64468050
Septic shock 17.55 11.32 97 30339 105340 64362956
Quality of life decreased 17.53 11.32 20 30416 7786 64460510
Macular hole 17.47 11.32 8 30428 726 64467570
Limb discomfort 17.21 11.32 39 30397 27136 64441160
Metabolic acidosis 17.18 11.32 6 30430 70952 64397344
Injection site pain 16.91 11.32 100 30336 111308 64356988
Tarsal tunnel syndrome 16.90 11.32 7 30429 498 64467798
Purpura senile 16.82 11.32 7 30429 504 64467792
Retinal exudates 16.82 11.32 9 30427 1141 64467155
Pancytopenia 16.80 11.32 26 30410 143283 64325013
Aspirin-exacerbated respiratory disease 16.75 11.32 9 30427 1151 64467145
Retinal oedema 16.73 11.32 8 30428 800 64467496
Resorption bone increased 16.69 11.32 9 30427 1159 64467137
Dizziness 16.57 11.32 290 30146 429873 64038423
Infection 16.48 11.32 146 30290 184734 64283562
Bursitis infective 16.46 11.32 9 30427 1191 64467105
Mobility decreased 16.37 11.32 82 30354 85758 64382538
Subretinal fibrosis 16.17 11.32 5 30431 151 64468145
Drug reaction with eosinophilia and systemic symptoms 16.16 11.32 3 30433 54214 64414082
Arthritis infective 15.76 11.32 18 30418 7012 64461284
Pneumonia lipoid 15.74 11.32 5 30431 165 64468131
Retinal fibrosis 15.58 11.32 3 30433 10 64468286
Vertigo positional 15.39 11.32 12 30424 2899 64465397
Injection site fibrosis 15.36 11.32 3 30433 11 64468285
Rapidly progressive osteoarthritis 15.36 11.32 3 30433 11 64468285
Application site pruritus 15.35 11.32 13 30423 3526 64464770
Distal intestinal obstruction syndrome 15.33 11.32 7 30429 631 64467665
Ear discomfort 15.25 11.32 18 30418 7262 64461034
Application site pain 15.22 11.32 14 30422 4234 64464062
Scleral disorder 15.07 11.32 5 30431 190 64468106
Conjunctival haemorrhage 15.05 11.32 15 30421 5006 64463290
Vision blurred 14.97 11.32 83 30353 90233 64378063
Endometrial thickening 14.94 11.32 5 30431 195 64468101
Delirium 14.88 11.32 7 30429 69187 64399109
Somnolence 14.82 11.32 48 30388 203597 64264699
Vitreous haemorrhage 14.77 11.32 12 30424 3073 64465223
Drug specific antibody present 14.72 11.32 15 30421 5139 64463157
Pain 14.66 11.32 353 30083 553158 63915138
Conjunctival oedema 14.65 11.32 8 30428 1056 64467240
Iridoschisis 14.61 11.32 3 30433 15 64468281
Expired product administered 14.57 11.32 16 30420 5971 64462325
Arthralgia 14.55 11.32 291 30145 441969 64026327
Macular ischaemia 14.22 11.32 4 30432 86 64468210
Peripheral swelling 14.17 11.32 156 30280 208997 64259299
Skin burning sensation 14.16 11.32 21 30415 10562 64457734
Diabetic ulcer 13.78 11.32 5 30431 249 64468047
Respiratory arrest 13.68 11.32 4 30432 52981 64415315
Cortisol decreased 13.67 11.32 9 30427 1668 64466628
Anterior chamber inflammation 13.64 11.32 6 30430 495 64467801
Visual field defect 13.64 11.32 18 30418 8128 64460168
Anterior chamber cell 13.62 11.32 7 30429 817 64467479
Retinal tear 13.43 11.32 8 30428 1246 64467050
Periphlebitis 13.40 11.32 3 30433 24 64468272
Plethoric face 13.29 11.32 3 30433 25 64468271
Type I hypersensitivity 13.24 11.32 12 30424 3562 64464734
Upper respiratory tract infection bacterial 13.22 11.32 4 30432 112 64468184
Retinal occlusive vasculitis 13.18 11.32 3 30433 26 64468270
Arthropathy 13.18 11.32 100 30336 120867 64347429
Mycobacterium kansasii infection 13.15 11.32 5 30431 284 64468012
Foot deformity 13.14 11.32 26 30410 16478 64451818
Seizure 13.09 11.32 38 30398 166854 64301442
Cerebral haemorrhage 12.93 11.32 4 30432 51086 64417210
Visual impairment 12.90 11.32 69 30367 74008 64394288
Myocardial infarction 12.83 11.32 38 30398 165783 64302513
Ocular hyperaemia 12.78 11.32 31 30405 22533 64445763
Pupillary reflex impaired 12.74 11.32 11 30425 3062 64465234
Prescribed underdose 12.71 11.32 27 30409 17988 64450308
Confusional state 12.58 11.32 72 30364 261072 64207224
Cataract nuclear 12.57 11.32 7 30429 960 64467336
Joint injury 12.44 11.32 31 30405 22916 64445380
Condition aggravated 12.22 11.32 245 30191 372181 64096115
Melaena 12.18 11.32 5 30431 53543 64414753
Steroid withdrawal syndrome 12.15 11.32 6 30430 644 64467652
Parakeratosis 12.15 11.32 5 30431 350 64467946
Intracranial hypotension 12.14 11.32 5 30431 351 64467945
Lactic acidosis 12.04 11.32 7 30429 61403 64406893
Cardiac failure 12.02 11.32 28 30408 132345 64335951
Retinoschisis 12.01 11.32 3 30433 40 64468256
Dehydration 11.99 11.32 57 30379 216706 64251590
Gamma-glutamyltransferase increased 11.92 11.32 4 30432 48506 64419790
Therapeutic product effect decreased 11.81 11.32 94 30342 115257 64353039
Choroiditis 11.81 11.32 7 30429 1080 64467216
Renal failure 11.76 11.32 45 30391 181643 64286653
Shared psychotic disorder 11.74 11.32 3 30433 44 64468252
Septic arthritis staphylococcal 11.63 11.32 6 30430 706 64467590
Erythema multiforme 11.62 11.32 24 30412 15677 64452619
Stomatitis 11.60 11.32 90 30346 109515 64358781
Retinal ischaemia 11.57 11.32 6 30430 714 64467582
Dermatophytosis 11.50 11.32 5 30431 401 64467895
Urticaria 11.45 11.32 113 30323 147204 64321092
Skin haemorrhage 11.44 11.32 17 30419 8568 64459728
Injection site reaction 11.44 11.32 48 30388 46616 64421680
Vaginal haemorrhage 11.41 11.32 27 30409 19317 64448979
Blindness unilateral 11.41 11.32 15 30421 6746 64461550

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:50857 anti-allergic drugs
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Cerebral edema indication 2032001
Lichen planus indication 4776004 DOID:9201
Berylliosis indication 8247009 DOID:10322
Psoriasis indication 9014002 DOID:8893
Ankylosing spondylitis indication 9631008 DOID:7147
Rheumatic heart disease indication 23685000
Atopic dermatitis indication 24079001 DOID:3310
Inflammatory bowel disease indication 24526004 DOID:0050589
Multiple sclerosis indication 24700007 DOID:2377
Severe adrenal insufficiency indication 24867002
Sarcoidosis indication 31541009 DOID:11335
Idiopathic thrombocytopenic purpura indication 32273002 DOID:8924
Psoriasis with arthropathy indication 33339001
Keloid scar indication 33659008
Crohn's disease indication 34000006
Tendinitis indication 34840004 DOID:971
Erythema multiforme indication 36715001
Contact dermatitis indication 40275004 DOID:2773
Angioedema indication 41291007 DOID:1558
Humoral hypercalcemia of malignancy indication 47709007
Articular gout indication 48440001 DOID:13189
Candidiasis of skin indication 49883006
Seborrheic dermatitis indication 50563003 DOID:8741
Edema of larynx indication 51599000
Nephrotic syndrome indication 52254009 DOID:1184
Lichen simplex chronicus indication 53891004
Systemic lupus erythematosus indication 55464009 DOID:9074
Allergic rhinitis indication 61582004
Löffler's syndrome indication 64936001 DOID:9503
Pemphigus indication 65172003 DOID:9182
Granuloma annulare indication 65508009 DOID:3777
Tenosynovitis indication 67801009 DOID:970
Alopecia areata indication 68225006 DOID:986
Rheumatoid arthritis indication 69896004 DOID:7148
Transfusion reaction due to serum protein reaction indication 72284000
Epicondylitis indication 73583000 DOID:14087
Acquired thrombocytopenia indication 74576004 DOID:11126
Sympathetic uveitis indication 75315001 DOID:12029
Thyroiditis indication 82119001 DOID:7166
Bursitis indication 84017003 DOID:2965
Autoimmune disease indication 85828009
Infection by larvae of Trichinella spiralis indication 88264003
Pruritus ani indication 90446007
Acute lymphoid leukemia indication 91857003 DOID:9952
Subacute bursitis indication 109298000
Dermatitis herpetiformis indication 111196000 DOID:8505
Hodgkin's disease indication 118599009
Non-Hodgkin's lymphoma indication 118601006
Mycosis fungoides indication 118618005
Uveitis indication 128473001 DOID:13141
Aspiration pneumonitis indication 155597006
Asthma indication 195967001 DOID:2841
Discoid lupus erythematosus indication 200938002
Plaque psoriasis indication 200965009
Transplanted organ rejection indication 213148006
Scalp psoriasis indication 238608008
Adrenogenital disorder indication 267395000 DOID:0050811
Pruritus of genital organs indication 267802000
Eruption of skin indication 271807003 DOID:0050486
Seasonal allergic rhinitis indication 367498001
Disorder of eye indication 371405004 DOID:5614
Adrenal cortical hypofunction indication 386584007 DOID:10493
Erythroderma indication 399992009
Primary cutaneous T-cell lymphoma indication 400122007
Asthma management indication 406162001
Autoimmune hemolytic anemia indication 413603009 DOID:718
Giant cell arteritis indication 414341000 DOID:13375
Synovitis indication 416209007 DOID:2703
Aphthous ulcer of mouth indication 426965005 DOID:9663
Post traumatic osteoarthritis indication 699262001
Synovitis due to Osteoarthritis indication
Cystic Aponeurosis Tumor indication
Gingival Disorders indication
Chronic Non-Allergic Rhinitis indication
Systemic Dermatomyositis indication
Allergic Rhinitis Prevention indication
Severe Ocular Inflammation indication
Erythroblastic Anemia indication
Transfusion Reaction Urticaria indication
Vitrectomy Adjunct to Enhance Visualization indication
Respiratory distress syndrome in the newborn off-label use 46775006
Congenital hypoplastic anemia off-label use 88854002 DOID:1339
Severe chronic obstructive pulmonary disease off-label use 313299006
Neonatal Bronchopulmonary Dysplasia off-label use
Infection by Strongyloides contraindication 1214006 DOID:10955
Mycosis contraindication 3218000 DOID:1564
Ocular hypertension contraindication 4210003 DOID:9282
Gastritis contraindication 4556007 DOID:4029
Inactive tuberculosis contraindication 11999007
Epistaxis contraindication 12441001
Peptic ulcer contraindication 13200003 DOID:750
Hypercholesterolemia contraindication 13644009
Measles contraindication 14189004 DOID:8622
Disease caused by parasite contraindication 17322007
Cirrhosis of liver contraindication 19943007 DOID:5082
Arginase deficiency contraindication 23501004 DOID:9278
Glaucoma contraindication 23986001 DOID:1686
Acute tuberculosis contraindication 25629007
Fungal infection of eye contraindication 31194008
Immunosuppression contraindication 38013005
Hypertensive disorder contraindication 38341003 DOID:10763
Infectious disease contraindication 40733004
Hypothyroidism contraindication 40930008 DOID:1459
Herpes zoster keratoconjunctivitis contraindication 42448002
Hypokalemia contraindication 43339004
Chronic heart failure contraindication 48447003
Tuberculosis of eye contraindication 49107007
Cerebral malaria contraindication 53622003 DOID:14069
Tuberculosis contraindication 56717001
Congenital hyperammonemia, type I contraindication 62522004
Osteoporosis contraindication 64859006 DOID:11476
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Hypopituitarism contraindication 74728003 DOID:9406
Candidiasis of mouth contraindication 79740000 DOID:14262
Perforation of nasal septum contraindication 80142000
Hyperglycemia contraindication 80394007 DOID:4195
Open-angle glaucoma contraindication 84494001 DOID:1067
Bacterial infectious disease contraindication 87628006
Muscle atrophy contraindication 88092000 DOID:767
Herpes simplex contraindication 88594005 DOID:8566
Operation on nose contraindication 88733004
Bilateral cataracts contraindication 95722004
Seizure disorder contraindication 128613002
Disorder of muscle contraindication 129565002 DOID:423
Ophthalmic herpes simplex contraindication 186542001
Anastomosis of intestine contraindication 235407009
Disease of liver contraindication 235856003 DOID:409
Telangiectasia disorder contraindication 247479008
Edema contraindication 267038008
Pathological fracture contraindication 268029009
Diverticulitis of gastrointestinal tract contraindication 271366000
Cerebral trauma contraindication 275382005
Oral infection contraindication 275393007
Varicella-zoster virus infection contraindication 309465005
Viral eye infection contraindication 312132001
Osteopenia contraindication 312894000
Skin irritation contraindication 367466007
Herpes zoster keratitis contraindication 397573005
Avascular necrosis of bone contraindication 397758007 DOID:10159
Citrullinemia contraindication 398680004 DOID:9273
Atrophoderma contraindication 399979006
Traumatic rupture of tendon contraindication 415749005
Exposure to varicella contraindication 444453009
Oropharyngeal Candidiasis contraindication
Arginosuccinate Lyase Deficiency contraindication
Nasal Septal Ulcers contraindication
Ornithine Carbamyltransferase Deficiency contraindication
Periodontal Infections contraindication
Nasal Trauma contraindication
Untreated Fungal Infection contraindication
Uncontrolled Bacterial Infections contraindication
Nasal Candidiasis contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

ProductApplicantIngredients
Vetalog Parenteral Boehringer lngelheim Animal Health USA Inc. 1
Panolog Ointment Zoetis Inc. 4
Triamcinolone Acetonide Boehringer lngelheim Animal Health USA Inc. 1
Vetalog Cream Boehringer lngelheim Animal Health USA Inc. 1
Panolog Cream Zoetis Inc. 4
Vetalog Oral Powder Boehringer lngelheim Animal Health USA Inc. 1
Vetalog Boehringer lngelheim Animal Health USA Inc. 1
Triamcinolone Acetonide Suspension Cronus Pharma Specialities India Private Limited 1
DERMA-VET Ointment Med-Pharmex Inc. 4
Animax Ointment Fougera Pharmaceuticals Inc. 4
Derma 4 Ointment Zoetis Inc. 4
Derm-Otic Ointment Zoetis Inc. 4
Genesis Topical Spray Virbac AH Inc. 1
Derma-Vet Cream Med-Pharmex Inc. 4
Medalone Cream Med-Pharmex Inc. 1
Animax Cream Fougera Pharmaceuticals Inc. 4

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.08 acidic
pKa2 11.78 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
40MG/ML XIPERE BAUSCH AND LOMB INC N211950 Oct. 22, 2021 RX SUSPENSION INJECTION 8636713 May 2, 2027 TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS
40MG/ML (40MG/ML) TRIESENCE NOVARTIS N022048 Nov. 29, 2007 RX INJECTABLE INTRAVITREAL 8211880 March 10, 2029 TREATMENT OF OPHTHALMIC DISORDERS
40MG/ML (40MG/ML) TRIESENCE NOVARTIS N022048 Nov. 29, 2007 RX INJECTABLE INTRAVITREAL 8211880 March 10, 2029 VISUALIZATION DURING VITRECTOMY PROCEDURES
32MG/VIAL ZILRETTA PACIRA PHARMS INC N208845 Oct. 6, 2017 RX FOR SUSPENSION, EXTENDED RELEASE INTRA-ARTICULAR 9555048 Aug. 4, 2031 METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE
40MG/ML XIPERE BAUSCH AND LOMB INC N211950 Oct. 22, 2021 RX SUSPENSION INJECTION 9636332 Nov. 8, 2033 TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
40MG/ML XIPERE BAUSCH AND LOMB INC N211950 Oct. 22, 2021 RX SUSPENSION INJECTION Oct. 22, 2024 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST EC50 9.30 WOMBAT-PK CHEMBL
Annexin A1 Cytosolic other WOMBAT-PK
Progesterone receptor Transcription factor Ki 7.64 DRUG MATRIX

External reference:

IDSource
D00983 KEGG_DRUG
4017597 VANDF
4017599 VANDF
C0040866 UMLSCUI
CHEBI:71418 CHEBI
CHEBI:9667 CHEBI
1TA PDB_CHEM_ID
CHEMBL1504 ChEMBL_ID
D014222 MESH_DESCRIPTOR_UI
2867 IUPHAR_LIGAND_ID
F446C597KA UNII
6436 PUBCHEM_CID
31307 PUBCHEM_CID
DB00620 DRUGBANK_ID
10759 RXNORM
2967 MMSL
4582 MMSL
5613 MMSL
5614 MMSL
6440 MMSL
d00620 MMSL
002188 NDDF
002189 NDDF
116594009 SNOMEDCT_US
395913005 SNOMEDCT_US
6028009 SNOMEDCT_US
C0040864 UMLSCUI
D014221 MESH_DESCRIPTOR_UI
755 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
KENALOG-40 HUMAN PRESCRIPTION DRUG LABEL 1 0003-0293 INJECTION, SUSPENSION 40 mg INTRAMUSCULAR NDA 21 sections
KENALOG-80 HUMAN PRESCRIPTION DRUG LABEL 1 0003-0315 INJECTION, SUSPENSION 80 mg INTRAMUSCULAR NDA 21 sections
KENALOG-10 HUMAN PRESCRIPTION DRUG LABEL 1 0003-0494 INJECTION, SUSPENSION 10 mg INTRA-ARTICULAR NDA 22 sections
TRIESENCE HUMAN PRESCRIPTION DRUG LABEL 1 0065-0543 INJECTION, SUSPENSION 40 mg OPHTHALMIC NDA 23 sections
Good Sense Nasal Allergy HUMAN OTC DRUG LABEL 1 0113-0443 SPRAY, METERED 55 ug NASAL ANDA 16 sections
basic care nasal allergy HUMAN OTC DRUG LABEL 1 0113-7005 SPRAY, METERED 55 ug NASAL ANDA 16 sections
triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0002 CREAM 5 mg TOPICAL ANDA 17 sections
triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0003 CREAM 0.25 mg TOPICAL ANDA 17 sections
triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0004 CREAM 1 mg TOPICAL ANDA 17 sections
Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0005 OINTMENT 0.25 mg TOPICAL ANDA 19 sections
Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0006 OINTMENT 1 mg TOPICAL ANDA 19 sections
Nystatin and Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 2 0168-0081 CREAM 1 mg TOPICAL ANDA 16 sections
Nystatin and Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 2 0168-0089 OINTMENT 1 mg TOPICAL ANDA 19 sections
triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0336 LOTION 0.25 mg TOPICAL ANDA 17 sections
triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0337 LOTION 1 mg TOPICAL ANDA 17 sections
TRIDERM HUMAN PRESCRIPTION DRUG LABEL 1 0316-0165 CREAM 0.25 mg TOPICAL ANDA 18 sections
TRIDERM HUMAN PRESCRIPTION DRUG LABEL 1 0316-0170 CREAM 1 mg TOPICAL ANDA 18 sections
TRIDERM HUMAN PRESCRIPTION DRUG LABEL 1 0316-0175 CREAM 5 mg TOPICAL ANDA 18 sections
Nystatin and Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 2 0316-0223 CREAM 1 mg TOPICAL ANDA 18 sections
Allergy Nasal HUMAN OTC DRUG LABEL 1 0363-0811 SPRAY, METERED 55 ug NASAL ANDA 16 sections
Allergy Nasal HUMAN OTC DRUG LABEL 1 0363-0811 SPRAY, METERED 55 ug NASAL ANDA 16 sections
Triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0440-0251 CREAM 1 mg TOPICAL ANDA 18 sections
Triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0440-0317 CREAM 0.25 mg TOPICAL ANDA 17 sections
Triamcinolone acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0440-0318 CREAM 5 mg TOPICAL ANDA 17 sections
Nystatin and Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 2 0472-0150 CREAM 1 mg TOPICAL ANDA 11 sections
Nystatin and Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 2 0472-0150 CREAM 1 mg TOPICAL ANDA 11 sections
Nystatin and Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 2 0472-0155 OINTMENT 1 mg TOPICAL ANDA 11 sections
Nystatin and Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 2 0472-0155 OINTMENT 1 mg TOPICAL ANDA 11 sections
Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0703-0241 INJECTION, SUSPENSION 40 mg INTRA-ARTICULAR ANDA 20 sections
Triamcinolone Acetonide HUMAN PRESCRIPTION DRUG LABEL 1 0703-0243 INJECTION, SUSPENSION 40 mg INTRA-ARTICULAR ANDA 20 sections